New oral option may offer relief for hereditary angioedema attacks
NCT ID NCT07759141
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This program provides access to an experimental oral medication called deucrictibant for people with hereditary angioedema (HAE) who have no satisfactory alternative treatments for acute attacks. Eligible participants, aged 12 to 75, take the capsule as needed to manage swelling episodes. The goal is to offer a potential treatment option when standard therapies are not available or effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- deucrictibant immediate-release (IR) capsule
- What this could lead to
- If successful, this could provide a new on-demand treatment option for people with hereditary angioedema who have run out of alternatives.
- What could go wrong
- This is an expanded access program, not a formal trial, so data on safety and effectiveness is limited. It is only for those with no other options, and benefits are not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection tame hereditary swelling attacks?
- Could a simple pill shield HAE patients from Procedure-Triggered attacks?
- Teens with rare swelling disorder get new drug tested
- New drug shows promise for controlling rare swelling disorder
- New drug navenibart aims to tame hereditary swelling attacks
- Gene therapy aims to stop painful swelling attacks in hereditary angioedema